Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.
Identifieur interne : 000166 ( PubMed/Corpus ); précédent : 000165; suivant : 000167Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.
Auteurs : Henry Ji ; Ying Yan ; Beibei Ding ; Wenzhong Guo ; Mark Brunswick ; Andreas Niethammer ; Williams Soohoo ; Robin Smith ; Alexis Nahama ; Yanliang ZhangSource :
- Medicine in drug discovery [ 2590-0986 ] ; 2020.
Abstract
A novel approach modifying cells to express viral markers to elicit protective immunity responses (decoy cellular vaccination) in the prevention of COVID-19 disease is currently being explored. Our approach entails utilizing SARS-CoV-2 Spike antigen-expressing, non-replicating cells as carriers and presenters of immunogenic antigens, so called "I-cells". By using irradiated cells as presenting vehicles of SARS-CoV-2 viral antigens(s) in a cellular context, these presented viral proteins can be recognized by the host immune system, thus, an efficient protective immune response might be elicited. Another advantage of this strategy is that the manufacturing process is scalable and yields uniform cell products allowing for "off-the-shelf" frozen supply availability. To prevent engraftment and proliferation of the cells after administration, the cells will be irradiated post-harvesting abolishing in vivo replication potential. Specifically, immunoreactive Spike-1 proteins from SARS-CoV-2 are expressed on the surface of irradiated target I-cells. Utilizing this innovative strategy, these viral antigen-displaying decoy cells will be developed as a vaccine to protect against COVID-19 disease.
DOI: 10.1016/j.medidd.2020.100026
PubMed: 32289117
Links to Exploration step
pubmed:32289117Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.</title><author><name sortKey="Ji, Henry" sort="Ji, Henry" uniqKey="Ji H" first="Henry" last="Ji">Henry Ji</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Yan, Ying" sort="Yan, Ying" uniqKey="Yan Y" first="Ying" last="Yan">Ying Yan</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Ding, Beibei" sort="Ding, Beibei" uniqKey="Ding B" first="Beibei" last="Ding">Beibei Ding</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Guo, Wenzhong" sort="Guo, Wenzhong" uniqKey="Guo W" first="Wenzhong" last="Guo">Wenzhong Guo</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Brunswick, Mark" sort="Brunswick, Mark" uniqKey="Brunswick M" first="Mark" last="Brunswick">Mark Brunswick</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Niethammer, Andreas" sort="Niethammer, Andreas" uniqKey="Niethammer A" first="Andreas" last="Niethammer">Andreas Niethammer</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Soohoo, Williams" sort="Soohoo, Williams" uniqKey="Soohoo W" first="Williams" last="Soohoo">Williams Soohoo</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Smith, Robin" sort="Smith, Robin" uniqKey="Smith R" first="Robin" last="Smith">Robin Smith</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Nahama, Alexis" sort="Nahama, Alexis" uniqKey="Nahama A" first="Alexis" last="Nahama">Alexis Nahama</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Yanliang" sort="Zhang, Yanliang" uniqKey="Zhang Y" first="Yanliang" last="Zhang">Yanliang Zhang</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32289117</idno><idno type="pmid">32289117</idno><idno type="doi">10.1016/j.medidd.2020.100026</idno><idno type="wicri:Area/PubMed/Corpus">000166</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000166</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.</title><author><name sortKey="Ji, Henry" sort="Ji, Henry" uniqKey="Ji H" first="Henry" last="Ji">Henry Ji</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Yan, Ying" sort="Yan, Ying" uniqKey="Yan Y" first="Ying" last="Yan">Ying Yan</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Ding, Beibei" sort="Ding, Beibei" uniqKey="Ding B" first="Beibei" last="Ding">Beibei Ding</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Guo, Wenzhong" sort="Guo, Wenzhong" uniqKey="Guo W" first="Wenzhong" last="Guo">Wenzhong Guo</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Brunswick, Mark" sort="Brunswick, Mark" uniqKey="Brunswick M" first="Mark" last="Brunswick">Mark Brunswick</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Niethammer, Andreas" sort="Niethammer, Andreas" uniqKey="Niethammer A" first="Andreas" last="Niethammer">Andreas Niethammer</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Soohoo, Williams" sort="Soohoo, Williams" uniqKey="Soohoo W" first="Williams" last="Soohoo">Williams Soohoo</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Smith, Robin" sort="Smith, Robin" uniqKey="Smith R" first="Robin" last="Smith">Robin Smith</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Nahama, Alexis" sort="Nahama, Alexis" uniqKey="Nahama A" first="Alexis" last="Nahama">Alexis Nahama</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Yanliang" sort="Zhang, Yanliang" uniqKey="Zhang Y" first="Yanliang" last="Zhang">Yanliang Zhang</name><affiliation><nlm:affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Medicine in drug discovery</title><idno type="eISSN">2590-0986</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A novel approach modifying cells to express viral markers to elicit protective immunity responses (decoy cellular vaccination) in the prevention of COVID-19 disease is currently being explored. Our approach entails utilizing SARS-CoV-2 Spike antigen-expressing, non-replicating cells as carriers and presenters of immunogenic antigens, so called "I-cells". By using irradiated cells as presenting vehicles of SARS-CoV-2 viral antigens(s) in a cellular context, these presented viral proteins can be recognized by the host immune system, thus, an efficient protective immune response might be elicited. Another advantage of this strategy is that the manufacturing process is scalable and yields uniform cell products allowing for "off-the-shelf" frozen supply availability. To prevent engraftment and proliferation of the cells after administration, the cells will be irradiated post-harvesting abolishing in vivo replication potential. Specifically, immunoreactive Spike-1 proteins from SARS-CoV-2 are expressed on the surface of irradiated target I-cells. Utilizing this innovative strategy, these viral antigen-displaying decoy cells will be developed as a vaccine to protect against COVID-19 disease.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32289117</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2590-0986</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Medicine in drug discovery</Title><ISOAbbreviation>Med Drug Discov</ISOAbbreviation></Journal><ArticleTitle>Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.</ArticleTitle><Pagination><MedlinePgn>100026</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medidd.2020.100026</ELocationID><Abstract><AbstractText>A novel approach modifying cells to express viral markers to elicit protective immunity responses (decoy cellular vaccination) in the prevention of COVID-19 disease is currently being explored. Our approach entails utilizing SARS-CoV-2 Spike antigen-expressing, non-replicating cells as carriers and presenters of immunogenic antigens, so called "I-cells". By using irradiated cells as presenting vehicles of SARS-CoV-2 viral antigens(s) in a cellular context, these presented viral proteins can be recognized by the host immune system, thus, an efficient protective immune response might be elicited. Another advantage of this strategy is that the manufacturing process is scalable and yields uniform cell products allowing for "off-the-shelf" frozen supply availability. To prevent engraftment and proliferation of the cells after administration, the cells will be irradiated post-harvesting abolishing in vivo replication potential. Specifically, immunoreactive Spike-1 proteins from SARS-CoV-2 are expressed on the surface of irradiated target I-cells. Utilizing this innovative strategy, these viral antigen-displaying decoy cells will be developed as a vaccine to protect against COVID-19 disease.</AbstractText><CopyrightInformation>© 2020 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Henry</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Beibei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Wenzhong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunswick</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niethammer</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>SooHoo</LastName><ForeName>Williams</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ 07102, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nahama</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yanliang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Sorrento Therapeutics, Inc., 4955 Directors Place, San Diego, CA 92121, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Med Drug Discov</MedlineTA><NlmUniqueID>101765689</NlmUniqueID><ISSNLinking>2590-0986</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antigen</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Transgenic cell vaccination</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>The authors are employed (or Directors) of Sorrento Therapeutics, Inc. The current discovery strategy is being implemented for vaccine development under the I-Cell™ label and within Sorrento's cGMP manufacturing facilities.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>03</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32289117</ArticleId><ArticleId IdType="doi">10.1016/j.medidd.2020.100026</ArticleId><ArticleId IdType="pii">S2590-0986(20)30013-0</ArticleId><ArticleId IdType="pii">100026</ArticleId><ArticleId IdType="pmc">PMC7144842</ArticleId></ArticleIdList><pmc-dir>pmcsd</pmc-dir>
<ReferenceList><Reference><Citation>PLoS One. 2012;7(4):e35421</Citation><ArticleIdList><ArticleId IdType="pubmed">22536382</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Pediatr Res. 2015 Nov;78(5):483-91</Citation><ArticleIdList><ArticleId IdType="pubmed">26267154</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunology. 1994 Sep;83(1):75-80</Citation><ArticleIdList><ArticleId IdType="pubmed">7821970</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Cancer. 1976 Oct 15;18(4):421-31</Citation><ArticleIdList><ArticleId IdType="pubmed">789258</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000166 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000166 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:32289117
|texte= Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:32289117" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |